Lab Home | Phone | Search
Center for Nonlinear Studies  Center for Nonlinear Studies
 Home 
 People 
 Current 
 Affiliates 
 Alumni 
 Visitors 
 Students 
 Research 
 ICAM-LANL 
 Quantum 
 Publications 
 Publications 
 2007 
 2006 
 2005 
 2004 
 2003 
 2002 
 2001 
 2000 
 <1999 
 Conferences 
 Workshops 
 Sponsorship 
 Talks 
 Colloquia 
 Colloquia Archive 
 Seminars 
 Postdoc Seminars Archive 
 Quantum Lunch 
 CMS Colloquia 
 Q-Mat Seminars 
 Q-Mat Seminars Archive 
 Archive 
 Kac Lectures 
 Dist. Quant. Lecture 
 Ulam Scholar 
 Colloquia 
 
 Jobs 
 Students 
 Summer Research 
 Student Application 
 Visitors 
 Description 
 Past Visitors 
 Services 
 General 
 PD Travel Request 
 
 History of CNLS 
 
 Maps, Directions 
 CNLS Office 
 T-Division 
 LANL 
 
Tuesday, April 28, 2015
10:00 AM - 11:00 AM
Chemistry Auditorium (TA-46), Building 535, Room 103

Seminar

Pathogen Mimicking Nanovaccine and Nanotherapeutic Platform Technology: A New Paradigm

Balaji Narasimhan
Department of Chemical and Biological Engineering Iowa State University

The design of vaccines and therapeutics to address infectious and tropical diseases is fraught with challenges, including poor immunogenicity, drug toxicity, and the need for multiple doses, needle-based methods, and cold storage. We have developed a cross-disciplinary approach (see Figure) at the intersection of polymer chemistry, nanotechnology, and immunology to enable the molecular design of a safe and efficacious nanovaccine and nanotherapeutic platform based on biodegradable amphiphilic polyanhydride nanoparticles that can meet these challenges and address both pre- and post-exposure to pathogens. We have shown using a bottom-up approach that these nano-adjuvants can mimic a natural infection and induce robust immune responses with long-lived protection. The nanoparticles are safe when administered via multiple routes and can be designed to encapsulate fragile protein antigens and deliver them in a sustained manner to immune cells, facilitating the maintenance of antigen-specific CD8+ and CD4+ T cells. These particles can be used for effective intracellular delivery of diverse payloads in a single administration, which results in lower toxicity, faster killing, enhanced patient compliance, dose sparing, and cost savings. This technology has been applied to treat diseases caused by bacteria, viruses, and parasites. A major advantage of the platform technology is its room temperature stability for extended periods of time. This will obviate the “cold chain”, which is a major hurdle in the global deployment of vaccines and therapeutics. This rational approach for designing novel nanoscale adjuvants and therapeutics has the tantalizing potential to catalyze the development of next generation technologies against emerging and re-emerging diseases.

Host: Harshini Mukundan, 606-2122